GENZYME CORPORATION for GENZYME CORPORATION

Pharmacy PHA

Food and Drug Administration Safety and Innovation Act Implementation Biosimilars Exclusivity Period in Administration's Budget Proposal

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); SENATE

Budget/Appropriations BUD

FY 2013 Budget FY 2014 Budget

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Agency for Healthcare Research & Quality (AHRQ)

Taxation/Internal Revenue Code TAX

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics Extension of R& D Tax Credit Orphan Drug Tax CreditImplementation of American Taxpayer Relief Act of 2012

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE

Health Issues HCR

Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Drug Supply Chain SecurityH.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 AHRQ Studies of Orphan Drugs

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013

Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.

Contacted: Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 413 (113th), S. 77 (113th), S. 117 (113th)